US EditionBiomX Inc. Achieves Breakthrough in Treating Antibiotic-Resistant Infections
Summary by citybuzz.co
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
BiomX Inc. Achieves Breakthrough in Treating Antibiotic-Resistant Infections
BiomX Inc., a biotech company with a market cap of approximately $10 million, has made significant strides in the fight against antibiotic-resistant infections through its innovative bacteriophage therapy. The company’s recent Phase 2 clinical trials have shown promising results in treating diabetic foot osteomyelitis and cystic fibrosis, conditions that have seen little innovation in treatment options over the past two decades. The diabetic foo…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
